Interest in taking HT for menopause in Europe 2020

According to a survey carried out in five European countries in 2020, almost 70 percent of women who were eligible for hormone therapy (HT) in Spain were adverse to taking the medication. Over a fifth of respondents in Germany said they were HT contraindicated which meant they were advised against using it due to certain conditions.

Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020

Characteristic	France	Germany	Italy	Spain	United Kingdom
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

June 2022

More information

Region

France, Germany, Italy, Spain, United Kingdom

Survey time period

February to October, 2020

Number of respondents

1,168 respondents

Age group

40-65 years

Special properties

Menopausal women eligible for HT

Method of interview

Questionnaire

Supplementary notes

Expanded meanings:
- HT contraindicated: Issues such as vaginal bleeding, metastatic solid tumor, tumor without metastasis, angina pectoris, myocardial infarction, thrombosis. coagulated blood clotting disorder, liver disease.
- Caution required at HT initiation - Conditions requiring a cardiovascular or breast cancer evaluation before HT, current smoker, BMI overweight, family or personal history of breast cancer, history of migraine, diabetes, and elevated cholesterol/hyperlipidemia.

Citation formats